Intaglietta Marcos, Cabrales Pedro, Tsai Amy G
Department of Bioengineering, University of California, San Diego, La Jolla, California 92093-0412, USA.
Annu Rev Biomed Eng. 2006;8:289-321. doi: 10.1146/annurev.bioeng.8.061505.095713.
The development of an alternative to natural blood has evolved from the initial goal of replicating blood properties to the current objective of formulating a fluid that can be used to replace blood while preserving microvascular function and delivering oxygen. The properties of this fluid are counterintuitive and different from blood because it has high viscosity, oxygen affinity, and a low oxygen carrier concentration when compared with blood. The optimal oxygen carrier devised presently is poly-ethylene-conjugated human hemoglobin, a material demonstrated to be vasoinactive and void of the toxicities present in previous hemoglobin formulations. A feature of this material is that it is effective in small quantities, and therefore amplifies the equivalent supply of blood derived from blood donations.
人造血液的发展已从最初复制血液特性的目标,演变为当前配制一种可用于替代血液,同时保留微血管功能并输送氧气的液体的目标。这种液体的特性与血液不同且违反直觉,因为与血液相比,它具有高粘度、高氧亲和力和低氧载体浓度。目前设计的最佳氧载体是聚乙二醇共轭人血红蛋白,这种材料已被证明无血管活性,且不存在先前血红蛋白制剂中的毒性。这种材料的一个特点是用量少却效果显著,因此扩大了来自献血的等效血液供应。